Sarepta Therapeutics Reports 34% Revenue Decline in Q2 2026 Amid Restructuring Efforts

Sarepta Therapeutics, Inc. reported a significant decline in financial performance for the second quarter of 2026, with total revenues of $401.3 million, down 34% from $611.1 million in the same period last year. The decrease was primarily driven by a 36% drop in product revenues, which totaled $328.7 million, compared to $513.1 million in the prior year. The company attributed this decline to reduced sales of its gene therapy product, ELEVIDYS, which saw a 65% decrease in revenue due to changes in demand following safety events and subsequent label updates limiting its use to ambulatory patients only.

In contrast, collaboration and other revenues increased by 104% to $472.9 million for the six months ended June 30, 2026, compared to $231.3 million in the same period of 2025. This increase was largely due to a $365 million revenue recognition related to Roche's declined option to acquire certain program rights and a $40 million milestone payment for the first commercial dosing of ELEVIDYS in Japan. The company also recorded a litigation contingency charge of $39 million during the quarter, reflecting ongoing patent litigations.

Sarepta's total expenses for the second quarter decreased by 22% to $388 million, down from $495.5 million in the previous year. Research and development costs saw a notable reduction of 55%, totaling $91.3 million, primarily due to a strategic restructuring plan that included workforce reductions and a pause in several clinical trials. Selling, general, and administrative expenses also decreased by 22% to $107.6 million, reflecting cost-cutting measures implemented as part of the restructuring.

As of June 30, 2026, Sarepta reported total assets of $3.19 billion, a decrease from $3.35 billion at the end of 2025. The company had $571.1 million in cash and cash equivalents, down from $801.3 million at the end of the previous year. Current liabilities also decreased significantly to $502.9 million from $1.1 billion, primarily due to a reduction in deferred revenue. The company’s total stockholders' equity increased to $1.53 billion, up from $1.14 billion, driven by a reduction in the accumulated deficit.

Looking ahead, Sarepta believes its current cash position, along with future cash inflows from operations and availability under its revolving credit facility, will be sufficient to fund its operational plans for at least the next twelve months. The company is focused on advancing its pipeline of RNA-targeted therapeutics and gene therapies while navigating the challenges posed by regulatory scrutiny and ongoing litigation.